Evidence map›Paper›PMID 41632594›Full record

ArticleBriefings in bioinformatics2026

PGVDA: a pathway-aggregated genetic dosage framework for interpretable disease classification using machine learning.

Sanghyun Shon, Younhee Ko, Hojin Yoon, Kyeongmin Kwak, Hwamin Lee

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sanghyun ShonDepartment of Biomedical Informatics, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.ORCID 0009-0008-6883-522X
Younhee KoDivision of Biomedical Engineering, Hankuk University of Foreign Studies, 81 Oedae-ro, Mohyeon-eup, Cheoin-gu, Yongin-si 17035, Gyeonggi-do, Republic of Korea.ORCID 0000-0002-2843-2222
Hojin YoonDepartment of Biomedical Informatics, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.ORCID 0000-0002-5144-6294
Kyeongmin KwakDepartment of Occupational and Environmental Medicine, Korea University Ansan Hospital, Korea University College of Medicine, 123 Jeokgeum-ro, Danwon-gu, Ansan-si, Gyeonggi-do 15355, Repubilc of Korea.ORCID 0000-0001-6296-8058
Hwamin LeeDepartment of Biomedical Informatics, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.ORCID 0000-0002-6482-3511

Funding

IITP (Institute of Information & Communications Technology Planning & Evaluation)-ICAN (ICT Challenge and Advanced Network of HRD) grant funded by the Korea government (Ministry of Science and ICT) IITP-2025-RS-2022-00156439National Research Foundation of Korea RS-2024-00441029
6 · The paper itself

Abstract

Although neuromuscular junction disorders (NMDs) and inflammatory polyneuropathies (IPNs) are biologically distinct, direct genetic comparisons between them remain limited, suggesting that additional underlying biological differences may yet be uncovered. Few studies have explored whether differences in variant patterns within shared biological pathways can be leveraged to distinguish NMDs and IPNs using machine learning (ML). We propose an interpretable ML framework based on Pathway-based Genetic Variant Dosage Average (PGVDA) to classify NMDs and IPNs and to identify key genes and pathways differentiating diseases. Using nonsynonymous variants from 667 UK Biobank participants, logistic regression identified disease-associated variants. Significant pathways were identified via pathway enrichment analysis with adjusted P-value < 0.05. PGVDA was calculated by assigning the log odds ratio to each variant dosage and then computing a weighted average at the pathway level. Dimensionality reduction was performed via hierarchical clustering based on gene-set overlaps and then PGVDAs with a variance inflation factor (VIF) > 10 were excluded. ML models were evaluated using leave-one-out cross validation. Utilizing the best-performing model, SHAP-based interpretation was applied using two distinct input configurations. Pathway-level interpretation using PGVDA input included stages of PGVDA scaling and ML-based classification, while variant-level interpretation using variant dosage input encompassed stages from odds ratio-based weight assignment to ML-based classification. Using logistic regression model with best performance, key differentiating five PGVDAs and 10 genes within each pathway were identified, suggesting that pathway-level variant aggregation enables accurate and interpretable classification of these two neuromuscular diseases. External validation is needed to ensure generalizability across populations.

Indexed as

Gene DosageMachine LearningNeuromuscular DiseasesPolyneuropathiesClassification AlgorithmsGenetic VariationHumansLogistic ModelsGenetic differentiationInflammatory polyneuropathyMachine learning classificationNeuromuscular junction disorderPathway-based aggregationSHAP analysis

Identifiers

PMID41632594
PMCPMC12866923

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.